Management of Atypical and Malignant Meningiomas: Role of High-dose, 3D-conformal Radiation Therapy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-06

AUTHORS

Eugen B. Hug, Alexander DeVries, Allan F. Thornton, John E. Munzenrider, Francisco S. Pardo, E. Tessa Hedley-Whyte, Marc R. Bussiere, Robert Ojemann

ABSTRACT

Objective Atypical and malignant meningiomas are at high risk for local failure. The role of radiation therapy (RT) and dose levels required to improve tumor control are poorly defined. This study reviews our experience with RT.Material and methods Thirty-one patients underwent fractionated RT for atypical (AM, 15 patients) or malignant meningioma (MM, 16 patients) of the cranium. Sixteen patients presented with primary and 15 with recurrent disease. Eight patients received RT following total resection, 21 patients after subtotal resection and 2 patient following biopsy only. RT was given using megavoltage photons in 15 patients and combined photons and 160 MeV protons in 16 patients. Total target doses ranged from 50 to 68 (AM, mean 62) and from 40 to 72 (MM, mean 58) Gy or CGE (= cobalt-gray-equivalent).Results With mean observation time of 59 months (range: 7–155 months) actuarial local control rates at 5- and 8-years were similar for both histologies (38% and 19% for AM and 52 and 17% for MM). However, significantly improved local control was observed for proton versus photon RT (80% versus 17% at 5 years, p = 0.003) and target doses ≥60 Gy for both, atypical (p = 0.025) and malignant meningioma (p = 0.0006).At time of analysis, 14/15 patients (93%) with AM and 6/16 (38%) with MM were alive. Three patients (19%) with MM developed distant metastasis. Actuarial 5- and 8-year survival rates for MM were significantly improved by use of proton over photon RT and radiation doses ≥60 CGE. Three patients developed symptomatic radiation damage after 59.3, 68.4 and 72 Gy/CGE.Conclusion Conformal, high dose RT resulted in significant improvement of local control for atypical and malignant meningiomas. Increased local control resulted also in improved rates of survival for patients with malignant meningioma. More... »

PAGES

151-160

References to SciGraph publications

  • 1975. Malignant Meningiomas in MENINGIOMAS DIAGNOSTIC AND THERAPEUTIC PROBLEMS MULTIPLE SCLEROSIS MISDIAGNOSIS FORENSIC PROBLEMS IN NEUROSURGERY
  • 1977-01. The significance of atypical mitoses in malignant meningiomas in ACTA NEUROPATHOLOGICA
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1023/a:1006434124794

    DOI

    http://dx.doi.org/10.1023/a:1006434124794

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1003841028

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/11083080


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adolescent", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Child", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Combined Modality Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cranial Irradiation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Follow-Up Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Life Tables", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Meningeal Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Meningioma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Metastasis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Recurrence, Local", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Photons", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proportional Hazards Models", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proton Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Radiation Injuries", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Radiotherapy Dosage", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Radiotherapy, High-Energy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Retrospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Salvage Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Survival Analysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Radiation Oncology, Dartmouth-Hitchcock Medical Center, NH, USA", 
              "id": "http://www.grid.ac/institutes/grid.413480.a", 
              "name": [
                "Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA", 
                "Harvard Cyclotron Laboratory, Cambridge, MA, USA", 
                "Radiation Oncology, Dartmouth-Hitchcock Medical Center, NH, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hug", 
            "givenName": "Eugen B.", 
            "id": "sg:person.01071247652.88", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071247652.88"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Radiation Oncology, University Hospital, Innsbruck, Austria", 
              "id": "http://www.grid.ac/institutes/grid.410706.4", 
              "name": [
                "Department of Radiation Oncology, University Hospital, Innsbruck, Austria"
              ], 
              "type": "Organization"
            }, 
            "familyName": "DeVries", 
            "givenName": "Alexander", 
            "id": "sg:person.0624465672.09", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624465672.09"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Harvard Cyclotron Laboratory, Cambridge, MA, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA", 
                "Harvard Cyclotron Laboratory, Cambridge, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Thornton", 
            "givenName": "Allan F.", 
            "id": "sg:person.01100344624.37", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100344624.37"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Harvard Cyclotron Laboratory, Cambridge, MA, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA", 
                "Harvard Cyclotron Laboratory, Cambridge, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Munzenrider", 
            "givenName": "John E.", 
            "id": "sg:person.0637022555.52", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637022555.52"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.38142.3c", 
              "name": [
                "Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Pardo", 
            "givenName": "Francisco S.", 
            "id": "sg:person.01076422010.55", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076422010.55"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.38142.3c", 
              "name": [
                "Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hedley-Whyte", 
            "givenName": "E. Tessa", 
            "id": "sg:person.01331023155.64", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331023155.64"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.38142.3c", 
              "name": [
                "Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bussiere", 
            "givenName": "Marc R.", 
            "id": "sg:person.01221457013.75", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221457013.75"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Harvard Cyclotron Laboratory, Cambridge, MA, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Harvard Cyclotron Laboratory, Cambridge, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ojemann", 
            "givenName": "Robert", 
            "id": "sg:person.01164414306.61", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164414306.61"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/978-3-642-66118-1_2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011527788", 
              "https://doi.org/10.1007/978-3-642-66118-1_2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00688070", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007371738", 
              "https://doi.org/10.1007/bf00688070"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2000-06", 
        "datePublishedReg": "2000-06-01", 
        "description": "Objective Atypical and malignant meningiomas are at high risk for local failure. The role of radiation therapy (RT) and dose levels required to improve tumor control are poorly defined. This study reviews our experience with RT.Material and methods Thirty-one patients underwent fractionated RT for atypical (AM, 15 patients) or malignant meningioma (MM, 16 patients) of the cranium. Sixteen patients presented with primary and 15 with recurrent disease. Eight patients received RT following total resection, 21 patients after subtotal resection and 2 patient following biopsy only. RT was given using megavoltage photons in 15 patients and combined photons and 160\u2009MeV protons in 16 patients. Total target doses ranged from 50 to 68 (AM, mean 62) and from 40 to 72 (MM, mean 58) Gy or CGE (= cobalt-gray-equivalent).Results With mean observation time of 59 months (range: 7\u2013155 months) actuarial local control rates at 5- and 8-years were similar for both histologies (38% and 19% for AM and 52 and 17% for MM). However, significantly improved local control was observed for proton versus photon RT (80% versus 17% at 5 years, p = 0.003) and target doses \u226560\u2009Gy for both, atypical (p = 0.025) and malignant meningioma (p = 0.0006).At time of analysis, 14/15 patients (93%) with AM and 6/16 (38%) with MM were alive. Three patients (19%) with MM developed distant metastasis. Actuarial 5- and 8-year survival rates for MM were significantly improved by use of proton over photon RT and radiation doses \u226560\u2009CGE. Three patients developed symptomatic radiation damage after 59.3, 68.4 and 72\u2009Gy/CGE.Conclusion Conformal, high dose RT resulted in significant improvement of local control for atypical and malignant meningiomas. Increased local control resulted also in improved rates of survival for patients with malignant meningioma.", 
        "genre": "article", 
        "id": "sg:pub.10.1023/a:1006434124794", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1094205", 
            "issn": [
              "0167-594X", 
              "1573-7373"
            ], 
            "name": "Journal of Neuro-Oncology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "48"
          }
        ], 
        "keywords": [
          "malignant meningiomas", 
          "radiation therapy", 
          "photon radiation therapy", 
          "local control", 
          "actuarial local control rate", 
          "high-dose radiation therapy", 
          "total target doses", 
          "Gy/CGE", 
          "local control rate", 
          "dose radiation therapy", 
          "mean observation time", 
          "recurrent disease", 
          "subtotal resection", 
          "total resection", 
          "distant metastasis", 
          "tumor control", 
          "control rate", 
          "high risk", 
          "target doses", 
          "high dose", 
          "patients", 
          "dose levels", 
          "Methods Thirty", 
          "survival rate", 
          "meningiomas", 
          "combined photons", 
          "time of analysis", 
          "local failure", 
          "doses", 
          "use of protons", 
          "resection", 
          "radiation doses", 
          "improved rates", 
          "therapy", 
          "significant improvement", 
          "observation time", 
          "megavoltage photons", 
          "biopsy", 
          "metastasis", 
          "histology", 
          "control", 
          "disease", 
          "Gy", 
          "atypicals", 
          "mM", 
          "survival", 
          "rate", 
          "risk", 
          "role", 
          "thirties", 
          "failure", 
          "damage", 
          "management", 
          "levels", 
          "cranium", 
          "study", 
          "time", 
          "AM", 
          "improvement", 
          "experience", 
          "objective", 
          "CGE", 
          "use", 
          "radiation damage", 
          "analysis", 
          "results", 
          "conformal", 
          "materials", 
          "protons", 
          "photons", 
          "MeV protons"
        ], 
        "name": "Management of Atypical and Malignant Meningiomas: Role of High-dose, 3D-conformal Radiation Therapy", 
        "pagination": "151-160", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1003841028"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1023/a:1006434124794"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "11083080"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1023/a:1006434124794", 
          "https://app.dimensions.ai/details/publication/pub.1003841028"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T20:49", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_336.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1023/a:1006434124794"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1006434124794'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1006434124794'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1006434124794'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1006434124794'


     

    This table displays all metadata directly associated to this object as RDF triples.

    307 TRIPLES      21 PREDICATES      125 URIs      115 LITERALS      33 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1023/a:1006434124794 schema:about N039899ad5e7242748c1ca4ebe9d0411f
    2 N0c324738a7dd4bbdb16f7d6c75a47fbe
    3 N0d4d4637bbeb4e50996860e4880bd1dc
    4 N16ebf0341800487287d09816e9604c3e
    5 N30d2764d7449474a95871647fffb64bd
    6 N4e9407d5481a4653808bdf941f00f16e
    7 N590f954b6f7c468d8360aea6414237b5
    8 N5d05c0a8a8c747d48f5a6e032e4f6425
    9 N6cb6dda49c56476ebec1cb11e0b5b2df
    10 N73500661cc5f470e95ca638d0bb5a62c
    11 N747c36d803c3436cb62cf3daf791bb27
    12 N82e7e173529c468c9f44bd0781805f5d
    13 N889ac96308724b698f0631f082be6c8d
    14 N8c591610b88a44b9af88425ab3cbda47
    15 N959bc300224a415c93931ab8e7caaf10
    16 N9772d8ba06004bcebf923206febf6abe
    17 Nbbccd27bad964079af79b74ec7bbbe17
    18 Nbcaed3fe6c2a4708b197aaab18da1b39
    19 Nc0dfa3c0d4f94c679ecaa7add6c5de3e
    20 Nc25879deeb4145c9afcc525311df26ff
    21 Ne2667c4dec97479e88d26fb479b28a0a
    22 Ne44f5d86292747bb9b05628fc3bc3dc2
    23 Ne646e1994fa44ecb9ad46adf4b382025
    24 Neb8785579b674fd19df7ff71d20eb9f5
    25 Nef31db1f6e1344bb82233042bfe65ea3
    26 Nfec2d5a133814b4385150563dd16f341
    27 anzsrc-for:11
    28 anzsrc-for:1112
    29 schema:author Nfa7881ab89e94c0093853f26546ecda4
    30 schema:citation sg:pub.10.1007/978-3-642-66118-1_2
    31 sg:pub.10.1007/bf00688070
    32 schema:datePublished 2000-06
    33 schema:datePublishedReg 2000-06-01
    34 schema:description Objective Atypical and malignant meningiomas are at high risk for local failure. The role of radiation therapy (RT) and dose levels required to improve tumor control are poorly defined. This study reviews our experience with RT.Material and methods Thirty-one patients underwent fractionated RT for atypical (AM, 15 patients) or malignant meningioma (MM, 16 patients) of the cranium. Sixteen patients presented with primary and 15 with recurrent disease. Eight patients received RT following total resection, 21 patients after subtotal resection and 2 patient following biopsy only. RT was given using megavoltage photons in 15 patients and combined photons and 160 MeV protons in 16 patients. Total target doses ranged from 50 to 68 (AM, mean 62) and from 40 to 72 (MM, mean 58) Gy or CGE (= cobalt-gray-equivalent).Results With mean observation time of 59 months (range: 7–155 months) actuarial local control rates at 5- and 8-years were similar for both histologies (38% and 19% for AM and 52 and 17% for MM). However, significantly improved local control was observed for proton versus photon RT (80% versus 17% at 5 years, p = 0.003) and target doses ≥60 Gy for both, atypical (p = 0.025) and malignant meningioma (p = 0.0006).At time of analysis, 14/15 patients (93%) with AM and 6/16 (38%) with MM were alive. Three patients (19%) with MM developed distant metastasis. Actuarial 5- and 8-year survival rates for MM were significantly improved by use of proton over photon RT and radiation doses ≥60 CGE. Three patients developed symptomatic radiation damage after 59.3, 68.4 and 72 Gy/CGE.Conclusion Conformal, high dose RT resulted in significant improvement of local control for atypical and malignant meningiomas. Increased local control resulted also in improved rates of survival for patients with malignant meningioma.
    35 schema:genre article
    36 schema:isAccessibleForFree false
    37 schema:isPartOf N40f0fda5572e483682350a418c981bda
    38 N84c18e3aec6c4cd98ff84a8fdaab0d0d
    39 sg:journal.1094205
    40 schema:keywords AM
    41 CGE
    42 Gy
    43 Gy/CGE
    44 MeV protons
    45 Methods Thirty
    46 actuarial local control rate
    47 analysis
    48 atypicals
    49 biopsy
    50 combined photons
    51 conformal
    52 control
    53 control rate
    54 cranium
    55 damage
    56 disease
    57 distant metastasis
    58 dose levels
    59 dose radiation therapy
    60 doses
    61 experience
    62 failure
    63 high dose
    64 high risk
    65 high-dose radiation therapy
    66 histology
    67 improved rates
    68 improvement
    69 levels
    70 local control
    71 local control rate
    72 local failure
    73 mM
    74 malignant meningiomas
    75 management
    76 materials
    77 mean observation time
    78 megavoltage photons
    79 meningiomas
    80 metastasis
    81 objective
    82 observation time
    83 patients
    84 photon radiation therapy
    85 photons
    86 protons
    87 radiation damage
    88 radiation doses
    89 radiation therapy
    90 rate
    91 recurrent disease
    92 resection
    93 results
    94 risk
    95 role
    96 significant improvement
    97 study
    98 subtotal resection
    99 survival
    100 survival rate
    101 target doses
    102 therapy
    103 thirties
    104 time
    105 time of analysis
    106 total resection
    107 total target doses
    108 tumor control
    109 use
    110 use of protons
    111 schema:name Management of Atypical and Malignant Meningiomas: Role of High-dose, 3D-conformal Radiation Therapy
    112 schema:pagination 151-160
    113 schema:productId N7731377eb7294766bcde64f90860a78e
    114 N8af972061b4e45cfbf7878a65b5a0bf1
    115 Ne1adb2d4bea04faf8ffa9286c8d1921f
    116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003841028
    117 https://doi.org/10.1023/a:1006434124794
    118 schema:sdDatePublished 2022-11-24T20:49
    119 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    120 schema:sdPublisher N8fee1fa5083d44caa47995f624b781d5
    121 schema:url https://doi.org/10.1023/a:1006434124794
    122 sgo:license sg:explorer/license/
    123 sgo:sdDataset articles
    124 rdf:type schema:ScholarlyArticle
    125 N039899ad5e7242748c1ca4ebe9d0411f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Combined Modality Therapy
    127 rdf:type schema:DefinedTerm
    128 N0c324738a7dd4bbdb16f7d6c75a47fbe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Male
    130 rdf:type schema:DefinedTerm
    131 N0d4d4637bbeb4e50996860e4880bd1dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Female
    133 rdf:type schema:DefinedTerm
    134 N14ece9cd56314d7eb4b290caa75f9a45 rdf:first sg:person.01100344624.37
    135 rdf:rest N344515e9c7fa40739a5cf69357666330
    136 N16ebf0341800487287d09816e9604c3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Humans
    138 rdf:type schema:DefinedTerm
    139 N30d2764d7449474a95871647fffb64bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Cranial Irradiation
    141 rdf:type schema:DefinedTerm
    142 N344515e9c7fa40739a5cf69357666330 rdf:first sg:person.0637022555.52
    143 rdf:rest N920bd552d43a42f58fd6e3f3cee5afbb
    144 N40f0fda5572e483682350a418c981bda schema:issueNumber 2
    145 rdf:type schema:PublicationIssue
    146 N4e9407d5481a4653808bdf941f00f16e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Survival Analysis
    148 rdf:type schema:DefinedTerm
    149 N590f954b6f7c468d8360aea6414237b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Radiotherapy Dosage
    151 rdf:type schema:DefinedTerm
    152 N5d05c0a8a8c747d48f5a6e032e4f6425 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Adult
    154 rdf:type schema:DefinedTerm
    155 N6cb6dda49c56476ebec1cb11e0b5b2df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Proportional Hazards Models
    157 rdf:type schema:DefinedTerm
    158 N73500661cc5f470e95ca638d0bb5a62c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Neoplasm Metastasis
    160 rdf:type schema:DefinedTerm
    161 N747c36d803c3436cb62cf3daf791bb27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Photons
    163 rdf:type schema:DefinedTerm
    164 N7731377eb7294766bcde64f90860a78e schema:name dimensions_id
    165 schema:value pub.1003841028
    166 rdf:type schema:PropertyValue
    167 N82e7e173529c468c9f44bd0781805f5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Adolescent
    169 rdf:type schema:DefinedTerm
    170 N84c18e3aec6c4cd98ff84a8fdaab0d0d schema:volumeNumber 48
    171 rdf:type schema:PublicationVolume
    172 N889ac96308724b698f0631f082be6c8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Salvage Therapy
    174 rdf:type schema:DefinedTerm
    175 N8af972061b4e45cfbf7878a65b5a0bf1 schema:name pubmed_id
    176 schema:value 11083080
    177 rdf:type schema:PropertyValue
    178 N8c591610b88a44b9af88425ab3cbda47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Radiotherapy, High-Energy
    180 rdf:type schema:DefinedTerm
    181 N8e912a59ae5148449a51f950f2d9d8e4 rdf:first sg:person.0624465672.09
    182 rdf:rest N14ece9cd56314d7eb4b290caa75f9a45
    183 N8fee1fa5083d44caa47995f624b781d5 schema:name Springer Nature - SN SciGraph project
    184 rdf:type schema:Organization
    185 N920bd552d43a42f58fd6e3f3cee5afbb rdf:first sg:person.01076422010.55
    186 rdf:rest Nf3d12ff76a404a1bb07757691c1077bf
    187 N959bc300224a415c93931ab8e7caaf10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    188 schema:name Radiation Injuries
    189 rdf:type schema:DefinedTerm
    190 N9772d8ba06004bcebf923206febf6abe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    191 schema:name Life Tables
    192 rdf:type schema:DefinedTerm
    193 Nbbccd27bad964079af79b74ec7bbbe17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Animals
    195 rdf:type schema:DefinedTerm
    196 Nbcaed3fe6c2a4708b197aaab18da1b39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    197 schema:name Proton Therapy
    198 rdf:type schema:DefinedTerm
    199 Nbdbf8408e8814572b5e421870a8b5f99 rdf:first sg:person.01221457013.75
    200 rdf:rest Nf04bfc846c0043fab7d39131c6a2819f
    201 Nc0dfa3c0d4f94c679ecaa7add6c5de3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    202 schema:name Middle Aged
    203 rdf:type schema:DefinedTerm
    204 Nc25879deeb4145c9afcc525311df26ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    205 schema:name Retrospective Studies
    206 rdf:type schema:DefinedTerm
    207 Ne1adb2d4bea04faf8ffa9286c8d1921f schema:name doi
    208 schema:value 10.1023/a:1006434124794
    209 rdf:type schema:PropertyValue
    210 Ne2667c4dec97479e88d26fb479b28a0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    211 schema:name Treatment Outcome
    212 rdf:type schema:DefinedTerm
    213 Ne44f5d86292747bb9b05628fc3bc3dc2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    214 schema:name Child
    215 rdf:type schema:DefinedTerm
    216 Ne646e1994fa44ecb9ad46adf4b382025 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    217 schema:name Meningioma
    218 rdf:type schema:DefinedTerm
    219 Neb8785579b674fd19df7ff71d20eb9f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    220 schema:name Meningeal Neoplasms
    221 rdf:type schema:DefinedTerm
    222 Nef31db1f6e1344bb82233042bfe65ea3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    223 schema:name Neoplasm Recurrence, Local
    224 rdf:type schema:DefinedTerm
    225 Nf04bfc846c0043fab7d39131c6a2819f rdf:first sg:person.01164414306.61
    226 rdf:rest rdf:nil
    227 Nf3d12ff76a404a1bb07757691c1077bf rdf:first sg:person.01331023155.64
    228 rdf:rest Nbdbf8408e8814572b5e421870a8b5f99
    229 Nfa7881ab89e94c0093853f26546ecda4 rdf:first sg:person.01071247652.88
    230 rdf:rest N8e912a59ae5148449a51f950f2d9d8e4
    231 Nfec2d5a133814b4385150563dd16f341 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    232 schema:name Follow-Up Studies
    233 rdf:type schema:DefinedTerm
    234 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    235 schema:name Medical and Health Sciences
    236 rdf:type schema:DefinedTerm
    237 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    238 schema:name Oncology and Carcinogenesis
    239 rdf:type schema:DefinedTerm
    240 sg:journal.1094205 schema:issn 0167-594X
    241 1573-7373
    242 schema:name Journal of Neuro-Oncology
    243 schema:publisher Springer Nature
    244 rdf:type schema:Periodical
    245 sg:person.01071247652.88 schema:affiliation grid-institutes:grid.413480.a
    246 schema:familyName Hug
    247 schema:givenName Eugen B.
    248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071247652.88
    249 rdf:type schema:Person
    250 sg:person.01076422010.55 schema:affiliation grid-institutes:grid.38142.3c
    251 schema:familyName Pardo
    252 schema:givenName Francisco S.
    253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076422010.55
    254 rdf:type schema:Person
    255 sg:person.01100344624.37 schema:affiliation grid-institutes:None
    256 schema:familyName Thornton
    257 schema:givenName Allan F.
    258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100344624.37
    259 rdf:type schema:Person
    260 sg:person.01164414306.61 schema:affiliation grid-institutes:None
    261 schema:familyName Ojemann
    262 schema:givenName Robert
    263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164414306.61
    264 rdf:type schema:Person
    265 sg:person.01221457013.75 schema:affiliation grid-institutes:grid.38142.3c
    266 schema:familyName Bussiere
    267 schema:givenName Marc R.
    268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221457013.75
    269 rdf:type schema:Person
    270 sg:person.01331023155.64 schema:affiliation grid-institutes:grid.38142.3c
    271 schema:familyName Hedley-Whyte
    272 schema:givenName E. Tessa
    273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331023155.64
    274 rdf:type schema:Person
    275 sg:person.0624465672.09 schema:affiliation grid-institutes:grid.410706.4
    276 schema:familyName DeVries
    277 schema:givenName Alexander
    278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624465672.09
    279 rdf:type schema:Person
    280 sg:person.0637022555.52 schema:affiliation grid-institutes:None
    281 schema:familyName Munzenrider
    282 schema:givenName John E.
    283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637022555.52
    284 rdf:type schema:Person
    285 sg:pub.10.1007/978-3-642-66118-1_2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011527788
    286 https://doi.org/10.1007/978-3-642-66118-1_2
    287 rdf:type schema:CreativeWork
    288 sg:pub.10.1007/bf00688070 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007371738
    289 https://doi.org/10.1007/bf00688070
    290 rdf:type schema:CreativeWork
    291 grid-institutes:None schema:alternateName Harvard Cyclotron Laboratory, Cambridge, MA, USA
    292 schema:name Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    293 Harvard Cyclotron Laboratory, Cambridge, MA, USA
    294 rdf:type schema:Organization
    295 grid-institutes:grid.38142.3c schema:alternateName Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    296 Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    297 schema:name Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    298 Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    299 rdf:type schema:Organization
    300 grid-institutes:grid.410706.4 schema:alternateName Department of Radiation Oncology, University Hospital, Innsbruck, Austria
    301 schema:name Department of Radiation Oncology, University Hospital, Innsbruck, Austria
    302 rdf:type schema:Organization
    303 grid-institutes:grid.413480.a schema:alternateName Radiation Oncology, Dartmouth-Hitchcock Medical Center, NH, USA
    304 schema:name Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    305 Harvard Cyclotron Laboratory, Cambridge, MA, USA
    306 Radiation Oncology, Dartmouth-Hitchcock Medical Center, NH, USA
    307 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...